BTIG analyst Ryan Zimmerman raised the firm’s price target on Penumbra (PEN) to $308 from $270 and keeps a Buy rating on the shares after its Q4 earnings beat. The company’s U.S. Thrombectomy continues to shine while its FY25 guidance sets up beats and raises, the analyst tells investors in a research note. Margins are likely to continue expanding rapidly in FY25 and beyond as product mix drives meaningful gross margin expansion, the firm added.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra price target raised to $260 from $240 at Morgan Stanley
- Penumbra price target raised to $328 from $305 at Baird
- Penumbra price target raised to $320 from $305 at UBS
- Penumbra price target raised to $340 from $323 at Canaccord
- Buy Rating Reaffirmed for Penumbra: Strong Financial Performance and Promising Growth Prospects Drive Upgraded Price Target